BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24683185)

  • 1. HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.
    Meza-Romero R; Benedek G; Yu X; Mooney JL; Dahan R; Duvshani N; Bucala R; Offner H; Reiter Y; Burrows GG; Vandenbark AA
    J Immunol; 2014 May; 192(9):4164-73. PubMed ID: 24683185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection.
    Benedek G; Meza-Romero R; Jordan K; Keenlyside L; Offner H; Vandenbark AA
    J Neuroinflammation; 2015 Jun; 12():123. PubMed ID: 26104759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased CD74 binding and EAE treatment efficacy of a modified DRα1 molecular construct.
    Meza-Romero R; Benedek G; Gerstner G; Kent G; Nguyen H; Offner H; Vandenbark AA
    Metab Brain Dis; 2019 Feb; 34(1):153-164. PubMed ID: 30353480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke.
    Benedek G; Zhu W; Libal N; Casper A; Yu X; Meza-Romero R; Vandenbark AA; Alkayed NJ; Offner H
    Metab Brain Dis; 2014 Mar; 29(1):37-45. PubMed ID: 24122483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Near Cure" treatment of severe acute EAE in MIF-1-deficient female and male mice with a bifunctional MHCII-derived molecular construct.
    Vandenbark AA; Meza-Romero R; Wiedrick J; Gerstner G; Seifert H; Kent G; Piechycna M; Benedek G; Bucala R; Offner H
    Cell Immunol; 2022 Aug; 378():104561. PubMed ID: 35738135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief report: Enhanced DRα1-mMOG-35-55 treatment of severe EAE in MIF-1-deficient male mice.
    Vandenbark AA; Meza-Romero R; Wiedrick J; Gerstner G; Headrick A; Kent G; Seifert H; Benedek G; Bucala R; Offner H
    Cell Immunol; 2021 Dec; 370():104439. PubMed ID: 34607646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects.
    Benedek G; Meza-Romero R; Andrew S; Leng L; Burrows GG; Bourdette D; Offner H; Bucala R; Vandenbark AA
    Eur J Immunol; 2013 May; 43(5):1309-21. PubMed ID: 23576302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance.
    Vandenbark AA; Meza-Romero R; Benedek G; Andrew S; Huan J; Chou YK; Buenafe AC; Dahan R; Reiter Y; Mooney JL; Offner H; Burrows GG
    J Autoimmun; 2013 Feb; 40():96-110. PubMed ID: 23026773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury.
    Yang L; Liu Z; Ren H; Zhang L; Gao S; Ren L; Chai Z; Meza-Romero R; Benedek G; Vandenbark AA; Offner H; Li M
    Metab Brain Dis; 2017 Oct; 32(5):1395-1402. PubMed ID: 28303450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicted structure of MIF/CD74 and RTL1000/CD74 complexes.
    Meza-Romero R; Benedek G; Leng L; Bucala R; Vandenbark AA
    Metab Brain Dis; 2016 Apr; 31(2):249-55. PubMed ID: 26851955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LPS-mediated cell surface expression of CD74 promotes the proliferation of B cells in response to MIF.
    Klasen C; Ziehm T; Huber M; Asare Y; Kapurniotu A; Shachar I; Bernhagen J; El Bounkari O
    Cell Signal; 2018 Jun; 46():32-42. PubMed ID: 29476963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of MIF and CD74 in leukemic cell lines: correlation to DR expression destiny.
    Georgouli M; Papadimitriou L; Glymenaki M; Patsaki V; Athanassakis I
    Biol Chem; 2016 Jun; 397(6):519-28. PubMed ID: 26866879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage migration inhibitory factor and CD74 regulate macrophage chemotactic responses via MAPK and Rho GTPase.
    Fan H; Hall P; Santos LL; Gregory JL; Fingerle-Rowson G; Bucala R; Morand EF; Hickey MJ
    J Immunol; 2011 Apr; 186(8):4915-24. PubMed ID: 21411731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury.
    Wang J; Ye Q; Xu J; Benedek G; Zhang H; Yang Y; Liu H; Meza-Romero R; Vandenbark AA; Offner H; Gao Y
    Transl Stroke Res; 2017 Jun; 8(3):284-293. PubMed ID: 27988839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer.
    Zheng YX; Yang M; Rong TT; Yuan XL; Ma YH; Wang ZH; Shen LS; Cui L
    World J Gastroenterol; 2012 May; 18(18):2253-61. PubMed ID: 22611320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MIF signal transduction initiated by binding to CD74.
    Leng L; Metz CN; Fang Y; Xu J; Donnelly S; Baugh J; Delohery T; Chen Y; Mitchell RA; Bucala R
    J Exp Med; 2003 Jun; 197(11):1467-76. PubMed ID: 12782713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling of both shared and distinct interactions between MIF and its homologue D-DT with their common receptor CD74.
    Meza-Romero R; Benedek G; Jordan K; Leng L; Pantouris G; Lolis E; Bucala R; Vandenbark AA
    Cytokine; 2016 Dec; 88():62-70. PubMed ID: 27573366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression.
    Frölich D; Blassfeld D; Reiter K; Giesecke C; Daridon C; Mei HE; Burmester GR; Goldenberg DM; Salama A; Dörner T
    Arthritis Res Ther; 2012 Mar; 14(2):R54. PubMed ID: 22404985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface expression of CD74 by type II alveolar epithelial cells: a potential mechanism for macrophage migration inhibitory factor-induced epithelial repair.
    Marsh LM; Cakarova L; Kwapiszewska G; von Wulffen W; Herold S; Seeger W; Lohmeyer J
    Am J Physiol Lung Cell Mol Physiol; 2009 Mar; 296(3):L442-52. PubMed ID: 19136583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High yield production of human invariant chain CD74 constructs fused to solubility-enhancing peptides and characterization of their MIF-binding capacities.
    Kok T; Wasiel AA; Dekker FJ; Poelarends GJ; Cool RH
    Protein Expr Purif; 2018 Aug; 148():46-53. PubMed ID: 29601965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.